F. Piscaglia

Hepatology · 2001–2018

A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom F. Piscaglia trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Llovet (in Hepatology)
  2. Jordi Bruix1 , 2 (in Hepatology)

Papers from F. Piscaglia's perspective

Ordered by how strongly the researchers F. Piscaglia trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  2. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
  3. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
  4. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
  5. Use of archived specimens in evaluation of prognostic and predictive biomarkers. (Journal of the National Cancer Institute)
  6. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
  7. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease (Hepatology)
  8. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. (Gastroenterology)
  9. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
  10. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (International Journal of Cancer)

Their papers